COVID-19(Corona virus disease 2019), which starts from Wuhan, China on December, 2019 spread rapidly to different countries of the world including Bangladesh. It affects huge impact on health care system. It’s a new disease with multisystem involvement. Physicians are experiencing new presentation of different cases and rare complication including arterial thrombosis. Few data is available regarding arterial thrombosis in SARS-CoV-2 infected patients. We are currently fighting with a 60 year old lady suffering from COVID-19 pneumonia with other co-morbidities developed severe arterial occlusion of right leg despite of taking anti platelet for long time for another cause. Patient developed irreversible right lower limb ischemia not improving with continuous infusion of unfractionated heparin followed by severe pulmonary embolism. So further study and recommendations will need to evaluate the cases and treatment in COVID-19 Patients with rare presentation. Bangladesh Journal of Infectious Diseases, October 2020;7(suppl_2):S50-S56

Background- Cardiovascular mortality is significantly higher in ESRD patient.There are various risk factors for development of cardiovascular diseases including traditional risk factors, factors unique to ESRD patients and emerging risk factors.It is believed that their combined actions are integrated in the progression of atherosclerosis and inflammation plays a central role. C-reactive protein is a valuable marker of inflammation. Determination of serum creactive protein levels may be a useful predictor of cardiovascular diseases in ESRD patients Objective-To find out relationship between c-reactive protein and cardiovascular diseases. Methods- This cross sectional study was carried out into department of Nephrology, Dhaka Medical College Hospital, Bangladesh following fulfillment of inclusion and exclusion criteria. For analytical purpose total study population were divided into two groups on the basis of creactive protein level. Patients having c-reactive protein £6 mg/L were considered as group A and >6 mg/L were considered as Group B. The differences between groups were analyzed by unpaired t-test, fisher’ exact test or chi-square (X2) test. Multivariable regression analysis was done to see the association between c-reactive protein and cardiovascular diseases. Results- Patients with raise c-reactive protein have significantly higher cardiovascular disease than that of normal c-reactive protein. Multivariable linear regression analysis after adjusting for age, sex, smoking and diabetes shows that subject with CRP £6 mg/L vs >6 mg/L had 1.51 (95% CI 1.02 to 2.19) times increase risk of having cardiovascular disease. Conclusion- Inflammatory process has a role in development of cardiovascular diseases in ESRD patient. J Shaheed Suhrawardy Med Coll 2020; 12(2): 95-99

Background: The pandemic corona virus disease 2019 (COVID-19) impacts a major global health crisis in the whole world including Bangladesh. Bangladesh is one of the world's high tuberculosis (TB) burden countries and TB is a major public health concern in the country. It is also observed that respiratory disease present with similar features of coronavirus disease, unfortunately and regrettably overlooked by the physicians worldwide due to the pandemic crisis. We presented a case of pulmonary TB and COVID-19 co-infection which has not been reported much. Case report: A 55 years old female presented with acute respiratory symptoms superimposed on chronic respiratory symptoms as she was suffering from bronchial asthma, diagnosed with severe pneumonia. Oropharyngeal and nasal swabs were found positive for coronavirus by real time polymerase chain reaction (RT-PCR) assay. Assessments of the previous history and clinical scenario also suggested investigations for TB. Sputum was positive for acid fast bacilli (AFB) and Gene Xpert detected Mycobacterium tuberculosis complex with rifampicin sensitivity. Patient was treated concomitantly for COVID-19 pneumonia with starting anti-tubercular drugs. So, physicians should suspect COVID-19 co infections with pulmonary TB while treating the patient presented with respiratory and systemic features. It should be kept in consideration for early diagnosis of pulmonary TB to reduce the morbidity and mortality of patients and to prevent transmission in the community from active sputum positive pulmonary TB.